Planegg/Martinsried, April 4, 2024.Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback